全球照护现场分子诊断市场规模（按产品/服务、技术、应用、最终用户、区域范围和预测）

照护现场分子诊断的市场规模与预测

预计 2024 年照护现场分子诊断市场规模将达到 36.1 亿美元，到 2032 年将达到 83.5 亿美元，2026 年至 2032 年的复合年增长率为 12.2%。

即时诊断 (POC) 分子诊断市场涵盖在患者所在地或附近检测和分析遗传物质（DNA 或 RNA）的诊断测试的开发、生产和销售。与需要将样本送到集中式设施进行分析的传统实验室分子测试不同，POC 分子诊断通常可在几分钟内快速提供结果，使医疗保健提供者能够及时做出明智的临床决策。该市场的发展得益于将复杂的测试流程微型化到紧凑便携的设备中，并利用聚合酵素链锁反应(PCR) 和等温扩增等技术。其主要目标是改善医疗保健的可近性，缩短週转时间，并加速治疗启动，尤其是在感染疾病、遗传性疾病和肿瘤学领域。

POC分子诊断市场的意义在于它能够弥合传统实验室检测与患者紧急需求之间的差距。其应用范围从急诊和医生办公室到远距诊所甚至居家医疗。该市场的主要驱动力包括感染疾病爆发、对快速和分散诊断解决方案日益增长的需求，以及将多个测试步骤整合到一个易于使用的平台的微流体和晶片实验室技术的进步。 COVID-19大流行起到了重要的催化剂作用，凸显了快速、准确和可访问的分子检测在疾病监测和控制中的关键作用。因此，随着人工智慧和机器学习等技术的整合越来越受到关注，以进一步提高诊断的准确性和效率，市场有望实现显着成长。

全球 POC 分子诊断市场驱动因素

受重塑医疗保健格局的许多因素共同推动，照护现场(POC) 分子诊断市场正经历强劲成长。从公共卫生危机到技术突破，这些因素正推动该产业朝着更分散、便利和以患者为中心的模式发展。以下分析将探讨推动该市场发展的关键因素，并重点介绍它们对临床和商业领域的影响。

感染疾病发生率上升：全球感染疾病发生率不断上升，包括流感、结核病和爱滋病毒等众所周知的病原体，以及新出现的威胁，是 POC 分子诊断市场的主要驱动力。传统的实验室诊断通常需要很长的周转时间，可能会延误治疗并导致高传染性疾病的传播。 POC 分子诊断提供了一个至关重要的解决方案，可在患者门口提供快速且准确的结果，从而实现即时的临床决策和有效的感染控制。 COVID-19 大流行起到了强大的催化剂作用，证明了快速 POC 检测在控制疫情和进行广泛监测方面发挥着至关重要的作用。人们对感染疾病诊断的认识和投资不断增长，对可携式、用户友好的分子检测平台产生了持续的需求。

对快速精准诊断的需求日益增长：在现代医疗保健领域，时间至关重要，对快速精准诊断的需求是不可动摇的市场驱动力。医疗保健提供者越来越重视能够提供快速、可靠结果并支援即时临床决策的诊断工具。从链球菌咽头炎到败血症，快速诊断可以显着改善患者预后，并减少不必要的抗生素处方。即时分子诊断能够在几分钟内提供实验室层级的结果，直接满足了这项需求。更有效率的医疗工作流程、更短的住院时间和更低的医疗总成本，进一步推动了这一趋势，因为早期准确的诊断可以预防疾病进展，并避免日后更复杂、更昂贵的治疗。

分子诊断技术的进步：分子诊断技术的持续进步正在显着推动市场发展。复杂实验室设备的小型化，加上微流体和奈米技术的突破，催生了高度紧凑、便携且用户友好的设备。这些技术创新使得将多个检测步骤整合到单一「晶片实验室」平台成为可能。此外，人工智慧 (AI) 和机器学习的结合，透过改善数据分析、减少假阳性并提供结果的自动化解读，提升了这些设备的性能和易用性。这些技术突破使先进的分子检测能够应用于更广泛的医疗机构和用户，从乡村诊所到医生诊所，从而拓宽了市场基础。

医疗服务日益去中心化：医疗服务去中心化的根本性转变是即时诊断（POC）分子诊断市场发展的强大驱动力。随着医疗模式不断发展，更加註重患者的便利性和可近性，对可在传统中心实验室之外使用的诊断解决方案的需求日益增长。这包括门诊护理、居家医疗和远距医疗的普及。可携式、易于使用的分子诊断设备非常适合这些环境，使医疗保健提供者能够在一次就诊中提供从咨询到诊断再到治疗的全方位护理。这一趋势在地域广阔和服务不足的社区尤其显着，因为在这些地区，集中检测的后勤挑战曾是及时医疗的一大障碍。

早期疾病检测需求：早期疾病检测需求是一个关键驱动因素，因为它直接关係到治疗效果的改善和患者的整体幸福感。无论是感染疾病、遗传性疾病或癌症，早期诊断都可能意味着轻微干预和危及生命的疾病之间的差异。即时诊断 (POC) 分子诊断透过提供快速且准确的筛检和检测能力，在这一领域发挥关键作用。例如，快速的即时诊断可以检测遗传易感性或病毒感染，从而製定快速、有针对性的治疗方案，最大限度地减少疾病对患者的影响。在医疗专业人士和消费者的支持下，对预防性和主动性医疗保健的日益重视正在推动这些技术在各种临床应用中的应用。

限制全球POC分子诊断市场的因素

儘管照护现场(POC) 分子诊断市场拥有巨大的潜力，有望改变医疗保健产业，但它仍面临许多重大限制因素，阻碍其广泛应用。从经济障碍到物流复杂性，再到监管障碍，必须应对这些挑战，才能充分发挥市场潜力，尤其是在全球环境日益多样化的今天。

分子诊断设备高成本：分子诊断设备成本高是一大限制因素，尤其是在医疗预算有限的中低收入地区。开发这些系统所需的先进技术、复杂组件和严谨的研发，导致其製造和最终采购价格高。这使得新兴经济体的小型诊所、医院和公共卫生系统难以投资和采用这些工具。不仅初始资本支出，专用检测试剂等耗材的经常性成本也进一步加重了经济负担，阻碍了其广泛应用。因此，市场往往集中在资源充足的医疗体系中，而许多服务匮乏的人仍然无法获得这些快速诊断服务。

技术专长有限：成功操作分子诊断设备需要专业训练和技术专长，这在偏远、资源有限的地区可能是一项重大挑战。儘管该行业正在朝着更用户友好、自动化的平台迈进，但许多系统仍然需要细緻的样品製备、精确的试剂处理以及谨慎的结果解读，以避免错误。在许多发展中国家，甚至在已开发国家的一些分散环境中，缺乏经过充分培训的人员会导致检测结果不准确、营运效率低下以及对技术缺乏信心。这种技能差距需要持续投资培训和教育项目，这可能会给医疗保健提供者带来额外的成本和物流挑战。

严格的监管要求：开发新型分子诊断技术是一个复杂的过程，需要遵守严格的监管要求，这可能会严重拖延其市场准入和商业化进程。美国（FDA）和欧洲（MDR）等主要市场的监管机构拥有严格且通常冗长的核准流程，以确保新设备的安全性和有效性。临床试验、检验研究和大量文件的投入给製造商，尤其是创新中小企业带来了沉重的负担。此外，在不同国家/地区应对不同法律规范的复杂性也为全球市场扩张带来了挑战，减缓了新型诊断解决方案到达最需要它们的最终用户的速度。

对准确性和灵敏度的担忧：虽然即时检测 (POC) 分子诊断通常被认为具有高度准确性，但在实际环境中对其准确性和灵敏度的担忧仍然是一个障碍。检测性能的差异可能源自于使用者错误、检体处理不当以及极端环境条件（例如温度和湿度）等因素。这些问题可能导致假阳性和假阴性，从而对患者照护、公共卫生和消费者信心造成潜在的严重后果。与条件严格控制且品质保证协议健全的传统实验室环境不同，POC 检测是分散式的，因此更容易受到这些变数的影响。克服这一限制需要不断改进稳健的技术，并在护理点实施严格的品管和品质保证措施。

开发中地区基础设施不足：在许多开发中地区，缺乏充足的医疗保健基础设施是即时检测（POC​​）分子诊断应用的主要障碍。许多设备需要稳定的电源、可靠的网路连接以进行资料传输，以及受控的储存环境以确保试剂和套件的正常运作。遗憾的是，这些基本要求在农村诊所和偏远地区往往无法满足。缺乏稳定的电网、缺乏敏感试剂的冷藏保管以及供应链物流不足，阻碍了这些技术的采用和有效使用，限制了它们在这些地区满足关键公共卫生需求的潜力。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查时间表
• 先决条件
• 限制

第二章调查方法

• 资料探勘
• 二次调查
• 初步调查
• 专家建议
• 品质检查
• 最终审核
• 数据三角测量
• 自下而上的方法
• 自上而下的方法
• 调查流程
• 资讯服务类型

第三章执行摘要

• 全球POC分子诊断市场概况
• 全球即时分子诊断市场的估计与预测
• 全球即时分子诊断市场的生态图谱
• 竞争分析漏斗图
• 全球即时诊断分子诊断市场绝对商机
• 全球即时分子诊断市场吸引力分析（按地区）
• 全球即时分子诊断市场吸引力分析（按产品和服务）
• 全球即时分子诊断市场吸引力分析（按技术）
• 全球 POC 分子诊断市场吸引力分析（按应用）
• 全球照护现场分子诊断市场吸引力分析（按最终用户）
• 全球分子诊断市场区域分析
• 全球照护现场分子诊断市场（按产品和服务划分）
• 全球POC分子诊断市场（按技术）
• 全球 POC 分子诊断市场（按应用）
• 全球POC分子诊断市场（按地区）
• 未来市场机会

第四章 市场展望

• 全球照护现场分子诊断市场
• 全球POC分子诊断市场展望
• 市场驱动因素
• 市场限制
• 市场趋势
• 市场机会
• 波特五力分析
  • 新进入者的威胁
  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 现有竞争对手之间的敌意
• 价值链分析
• 定价分析
• 宏观经济分析

第五章 产品/服务市场

• 概述
• 检测套组
• 仪器/分析仪
• 软体和服务

第六章 按技术分類的市场

• 概述
• RT PCR
• INAAT

第七章 按应用分類的市场

• 概述
• 癌症
• 感染疾病
• 血液学
• 内分泌学

第 8 章 最终用户市场

• 概述
• 医院和诊所
• 诊断中心

第九章 区域市场

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲
• 中东和非洲
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 其他中东和非洲地区

第十章 竞争格局

• 概述
• 主要发展策略
• 公司的地理分布
• 王牌矩阵
  • 积极的
  • 前线
  • 新兴
  • 创新者

第十一章 公司简介

• OVERVIEW
• ABBOTT LABORATORIES INC.
• ROCHE DIAGNOSTICS
• BIOMERIEUX SA
• DANAHER CORPORATION
• CEPHEID
• QIAGEN NV
• THERMO FISHER SCIENTIFIC INC.
• HOLOGIC INC.
• BIO RAD LABORATORIES INC.
• BECTON
• DICKINSON AND COMPANY
• GENMARK DIAGNOSTICS INC.
• MERIDIAN BIOSCIENCE INC.
• MESA BIOTECH INC.
• BIOCARTIS GROUP NV
• QUANTUMDX GROUP LIMITED

Point Of Care Molecular Diagnostics Market Size And Forecast

Point Of Care Molecular Diagnostics Market size was valued at USD 3.61 Billion in 2024 and is projected to reach USD 8.35 Billion by 2032, growing at a CAGR of 12.2% from 2026 to 2032.

The Point of Care (POC) Molecular Diagnostics Market encompasses the development, production, and sale of diagnostic tests that detect and analyze genetic material (DNA or RNA) at or near a patient's location. Unlike traditional lab based molecular tests that require samples to be sent to a centralized facility for analysis, POC molecular diagnostics provide rapid results, often within minutes, enabling healthcare providers to make timely and informed clinical decisions. This market is driven by the miniaturization of complex lab processes onto compact, portable devices, often leveraging technologies like Polymerase Chain Reaction (PCR) and isothermal amplification. The primary objective is to improve healthcare accessibility, reduce turnaround times, and facilitate faster treatment initiation, particularly for infectious disease, genetic disorders, and oncology.

The significance of the POC Molecular Diagnostics Market lies in its ability to bridge the gap between traditional laboratory testing and immediate patient needs. Its applications are widespread, from emergency departments and physician's offices to remote clinics and even home care settings. Key drivers for this market include the increasing prevalence of infectious diseases, a growing need for rapid and decentralized diagnostic solutions, and advancements in microfluidic and lab on a chip technologies that integrate multiple testing steps into a single, user friendly platform. The COVID 19 pandemic served as a major catalyst, highlighting the critical role of rapid, accurate, and accessible molecular testing in disease surveillance and control. As a result, the market is poised for significant growth, with a growing focus on integrating technologies like AI and machine learning to further enhance diagnostic accuracy and efficiency.

Global Point Of Care Molecular Diagnostics Market Drivers

The Point of Care (POC) Molecular Diagnostics market is experiencing robust growth, driven by a convergence of factors that are reshaping the healthcare landscape. From public health crises to technological breakthroughs, these drivers are collectively pushing the industry toward a more decentralized, accessible, and patient centric model. The following analysis explores the key forces propelling this market forward, highlighting their impact on both the clinical and commercial spheres.

Rising Prevalence of Infectious Diseases: The increasing global incidence of infectious diseases, including well known pathogens like influenza, tuberculosis, and HIV, as well as emerging threats, is a primary driver for the Point of Care Molecular Diagnostics market. Traditional lab based diagnostics often have a long turnaround time, which can delay treatment and contribute to the spread of highly contagious illnesses. POC molecular diagnostics offer a crucial solution by providing rapid and accurate results at or near the patient, enabling immediate clinical decisions and effective infection control. The COVID 19 pandemic served as a powerful catalyst, demonstrating the indispensable role of rapid POC testing in managing outbreaks and conducting widespread surveillance. This heightened awareness and investment in infectious disease diagnostics have created a sustained demand for portable, user friendly molecular testing platforms.

Growing Demand for Rapid and Accurate Diagnostics: In modern healthcare, time is a critical factor, and the demand for rapid and accurate diagnostics has become a non negotiable market driver. Healthcare providers are increasingly prioritizing diagnostic tools that can deliver fast, reliable results to enable immediate clinical decision making. For conditions ranging from strep throat to sepsis, a speedy diagnosis can dramatically improve patient outcomes and reduce the need for unnecessary antibiotic prescriptions. POC molecular diagnostics, with their ability to provide lab quality results in minutes, directly address this need. This trend is further supported by the push for more efficient healthcare workflows, shorter hospital stays, and a reduction in the overall cost of care, as early and accurate diagnosis can prevent the progression of diseases and avoid more complex and expensive treatments later on.

Advancements in Molecular Diagnostic Technologies: The market is being significantly propelled by continuous advancements in molecular diagnostic technologies. Miniaturization of complex lab equipment, coupled with breakthroughs in microfluidics and nanotechnology, has led to the creation of highly compact, portable, and user friendly devices. These innovations allow for the integration of multiple testing steps onto a single "lab on a chip" platform. Furthermore, the incorporation of artificial intelligence (AI) and machine learning is enhancing the performance and usability of these devices by improving data analysis, reducing false positives, and providing automated interpretation of results. These technological leaps are making sophisticated molecular testing more accessible to a wider range of healthcare settings and users, from rural clinics to physicians' offices, thereby broadening the market's reach.

Increasing Decentralization of Healthcare Services: A fundamental shift towards the decentralization of healthcare services is a powerful driver for the POC molecular diagnostics market. As healthcare models evolve to prioritize patient convenience and accessibility, there is a growing demand for diagnostic solutions that can be used outside of traditional centralized laboratories. This includes the proliferation of outpatient care, home healthcare, and remote clinics. Portable and easy to use molecular diagnostic devices are perfectly suited for these settings, allowing healthcare providers to offer a full spectrum of care, from consultation to diagnosis and treatment, in a single visit. This trend is particularly impactful in regions with vast geographic areas or underserved communities, where the logistical challenges of centralized testing have historically been a barrier to timely care.

Need for Early Disease Detection: The need for early disease detection is a critical driver, as it is directly linked to better treatment outcomes and overall patient well being. Whether for infectious diseases, genetic disorders, or cancer, diagnosing a condition in its early stages can be the difference between a minor intervention and a life threatening illness. Point of care molecular diagnostics play a vital role in this by providing rapid, accurate screening and detection capabilities. For example, a quick POC test for a genetic predisposition or a viral infection can lead to a prompt and targeted therapeutic plan, minimizing the disease's impact on the patient. This emphasis on proactive and preventative healthcare, championed by both medical professionals and consumers, is fueling the adoption of these technologies across various clinical applications.

Global Point Of Care Molecular Diagnostics Market Restraints

Despite its immense potential to transform healthcare, the Point of Care (POC) Molecular Diagnostics market faces several significant restraints that hinder its widespread adoption. These challenges, ranging from economic hurdles to logistical complexities and regulatory obstacles, must be addressed for the market to reach its full potential, particularly in diverse global settings.

High Cost of Molecular Diagnostic Devices: The high cost of molecular diagnostic devices is a major restraint, particularly in low and middle income regions where healthcare budgets are limited. The advanced technology, complex components, and rigorous R&D required to develop these systems lead to high manufacturing and final purchase prices. This makes it difficult for smaller clinics, physicians' offices, and public health systems in developing economies to invest in and adopt these tools. Beyond the initial capital outlay, the recurring cost of consumables, such as specialized assays and reagents, further adds to the financial burden, creating a barrier to widespread implementation. The market is therefore often concentrated in well funded healthcare systems, while many underserved populations remain without access to these rapid diagnostic capabilities.

Limited Technical Expertise: The successful operation of some molecular diagnostic devices requires specialized training and technical expertise, which can be a significant challenge in resource limited and remote settings. While the industry is moving towards more user friendly, automated platforms, many systems still require meticulous sample preparation, precise handling of reagents, and careful interpretation of results to avoid errors. The lack of adequately trained personnel in many developing regions, and even in some decentralized settings in developed countries, can lead to inaccurate test results, operational inefficiencies, and a lack of trust in the technology. This skill gap necessitates ongoing investment in training and education programs, which can be an additional cost and logistical challenge for healthcare providers.

Stringent Regulatory Requirements: The development of new molecular diagnostic products is a complex process, subject to stringent regulatory requirements that can significantly delay market entry and commercialization. Regulatory bodies in key markets like the United States (FDA) and Europe (MDR) have rigorous and often lengthy approval processes to ensure the safety and efficacy of new devices. This creates a significant burden for manufacturers, particularly smaller innovative companies, as it requires substantial investment in clinical trials, validation studies, and extensive documentation. The complexity of navigating different regulatory frameworks across various countries also poses a challenge for global market expansion, slowing down the pace at which novel diagnostic solutions can reach the end users who need them most.

Concerns Over Accuracy and Sensitivity: While POC molecular diagnostics are generally considered highly accurate, concerns over their accuracy and sensitivity in real world settings remain a restraint. Variability in test performance can arise from factors such as user error, improper sample handling, and extreme environmental conditions (e.g., temperature and humidity). These issues can lead to false positives or false negatives, which can have severe consequences for patient care, public health, and user trust. Unlike traditional laboratory settings where conditions are tightly controlled and quality assurance protocols are robust, the decentralized nature of POC testing makes it more susceptible to these variables. Overcoming this restraint requires continuous improvement in technology to enhance robustness and the implementation of rigorous quality control and quality assurance measures at the point of care.

Inadequate Infrastructure in Developing Regions: The lack of proper healthcare infrastructure in many developing regions is a major barrier to the adoption of POC molecular diagnostics. The successful operation of many devices requires a stable power supply, reliable internet connectivity for data transfer, and controlled storage environments for reagents and kits. Unfortunately, these basic requirements are often not met in rural clinics and remote areas. The absence of a stable electrical grid, a lack of refrigerated storage for sensitive reagents, and poor supply chain logistics can hinder the implementation and effective use of these technologies, limiting their potential to address critical public health needs in these regions.

Global Point Of Care Molecular Diagnostics Market Segmentation Analysis

The Point Of Care Molecular Diagnostics Market is segmented based on Product & Service, Technology, Application, End User, and Geography.

Point Of Care Molecular Diagnostics Market, By Product & Service

Assays & Kits

Instruments & Analyzers

Software & Services

Based on Product & Service, the Point Of Care Molecular Diagnostics Market is segmented into Assays & Kits, Instruments & Analyzers, and Software & Services. At VMR, we observe that the Assays & Kits segment is the dominant subsegment, holding the largest market share and driving the market's recurring revenue. Its dominance stems from its consumable nature; for every test performed on a POC molecular instrument, a specific assay or kit is required. This makes the segment's revenue stream consistent and directly tied to the utilization of the installed base of instruments. The high volume of infectious disease testing, particularly for respiratory illnesses and STIs, further propels this segment. According to recent reports, Assays & Kits accounted for a majority of the market share, with some data indicating it comprised over 50% of the market in 2024. This market is also characterized by continuous innovation, with companies constantly developing new and improved assays that are more sensitive, specific, and can detect multiple pathogens from a single sample (multiplexing), thus ensuring its ongoing dominance.

The Instruments & Analyzers subsegment is the second most dominant, playing a crucial role by providing the hardware necessary for molecular testing. While this segment has a higher average selling price and is not a recurring purchase like kits, its growth is driven by the increasing demand for compact, portable, and automated devices that can be used in decentralized settings. The market for instruments is highly competitive, with a focus on developing user friendly platforms that require minimal training. As the installed base of these instruments grows, it, in turn, fuels the demand for the Assays & Kits segment, creating a symbiotic relationship.

The Software & Services subsegment plays a supporting role by enhancing the functionality and usability of the hardware and kits. While it currently holds the smallest market share, its future potential is significant. This segment includes data management solutions, connectivity services for remote monitoring and result reporting, and maintenance services. The increasing digitalization of healthcare and the need for seamless data integration are poised to drive the growth of this subsegment, as it adds value beyond the physical products.

Point Of Care Molecular Diagnostics Market, By Technology

RT PCR

INAAT

Based on Technology, the Point Of Care Molecular Diagnostics Market is segmented into RT PCR and INAAT. At VMR, we observe that Real Time PCR (RT PCR) is the dominant subsegment, a position it maintains due to its unparalleled sensitivity, specificity, and quantitative accuracy, which are considered the gold standard in molecular diagnostics. The widespread adoption of RT PCR was significantly accelerated by the COVID 19 pandemic, where it became the primary method for virus detection, leading to a massive increase in its use in hospitals and decentralized settings globally. Even post pandemic, its extensive clinical utility continues in infectious disease testing for influenza, HIV, and various STIs. According to industry data, the RT PCR segment held approximately 45% of the point of care molecular diagnostics market in 2024, a testament to its reliability. The ongoing miniaturization and development of portable RT PCR systems have further solidified its dominance, enabling high quality, lab standard testing at or near the patient's location, particularly in North America, which has a highly advanced healthcare infrastructure and significant R&D investments.

The Isothermal Nucleic Acid Amplification Technology (INAAT) subsegment is the second most dominant, with a crucial role as a faster, more accessible, and often more cost effective alternative to RT PCR. Unlike RT PCR, INAAT does not require sophisticated thermal cycling equipment, allowing for simpler, battery powered devices suitable for use in resource limited settings and for at home testing. Its growth is driven by the demand for rapid, on the spot results, with technologies like Loop mediated Isothermal Amplification (LAMP) gaining significant traction. While INAAT is poised for a higher growth rate over the forecast period due to its operational simplicity and lower cost, its current market share is smaller, as it is still gaining trust and a wider range of applications compared to the established RT PCR.

Point Of Care Molecular Diagnostics Market, By Application

Cancer

Infectious Diseases

Hematology

Endocrinology

Based on Application, the Point Of Care Molecular Diagnostics Market is segmented into Cancer, Infectious Diseases, Hematology, and Endocrinology. At VMR, we observe that the Infectious Diseases subsegment is overwhelmingly dominant, holding the largest market share and serving as the primary growth engine for the overall market. This dominance is driven by the urgent need for rapid and accurate diagnosis of infectious pathogens, particularly in emergency settings, decentralized clinics, and remote locations. The segment's growth was significantly accelerated by the COVID 19 pandemic, which underscored the critical role of accessible and quick testing for effective disease management and public health surveillance. According to our analysis, the Infectious Diseases segment holds a market share of approximately 31.5% and is expected to continue its robust growth trajectory. The widespread adoption of highly accurate technologies like RT PCR for rapid testing of respiratory infections (e.g., COVID 19, influenza), sexually transmitted infections, and hospital acquired infections is a key driver. This segment is heavily relied upon by hospitals, clinics, and even at home users for timely diagnosis and to enable prompt treatment and infection control.

The Cancer subsegment is the second most dominant, and while it holds a smaller share, it is poised for the most significant future growth. Its role is becoming increasingly critical with the shift towards personalized medicine and the growing demand for early and precise cancer detection. Point of care molecular diagnostics in oncology are used to identify specific genetic mutations and biomarkers from a small sample, guiding treatment selection and monitoring therapy response. The growth in this segment is fueled by technological advancements like liquid biopsy, which provides a non invasive method for cancer detection, and the integration of AI to analyze complex genomic data. This segment is projected to grow at a high CAGR, with some forecasts placing it at over 12% through 2030, reflecting its importance in modern cancer care.

The remaining subsegments, Hematology and Endocrinology, play a supporting role, catering to more specialized and niche applications. The Hematology segment is used for rapid analysis of blood related disorders, while the Endocrinology segment focuses on hormone related conditions. While their market share is smaller, the ability to perform these tests at the point of care provides significant benefits in terms of reducing diagnostic delays and improving patient management, indicating their potential for targeted growth as the technology becomes more widespread and cost effective.

Point Of Care Molecular Diagnostics Market, By End User

Hospitals & Clinics

Diagnostic Centers

Based on End User, the Point Of Care Molecular Diagnostics Market is segmented into Hospitals & Clinics and Diagnostic Centers. At VMR, we observe that the Hospitals & Clinics segment is the dominant subsegment, commanding the largest market share and driving significant adoption of POC molecular diagnostics. This dominance is primarily due to the high volume of patients they serve and their critical need for rapid, accurate diagnostic solutions in emergency, critical care, and outpatient settings. The adoption is further fueled by the increasing prevalence of infectious diseases and the demand for timely clinical decisions to improve patient outcomes and streamline workflows. Data from various market reports suggests that hospitals and clinics account for over 40% of the market share, highlighting their role as the primary end users. The trend towards decentralizing testing from large, centralized labs to smaller, on site hospital or clinic labs is a major driver, as it reduces turnaround times, shortens hospital stays, and improves overall efficiency. The ability of POC molecular platforms to provide laboratory quality results with minimal technical expertise makes them a perfect fit for these settings.

The Diagnostic Centers segment is the second most dominant subsegment, playing a crucial role in providing specialized and often high volume testing services. While not always at the "point of care" in the same way as a hospital emergency room, these centers leverage molecular diagnostic technologies to offer a broad range of tests, from infectious disease panels to genetic screenings. Their growth is driven by the increasing demand for specialized testing services and the rising number of patients seeking preventative care and targeted diagnostics. Diagnostic centers often act as a bridge between physicians' offices and centralized labs, providing a more localized and convenient option for patients.

While not explicitly a subsegment in the provided list, the Homecare setting is an emerging end user with significant future potential. This segment, though currently holding a smaller share, is expected to grow rapidly due to the rising trend of at home testing, which offers convenience and accessibility. The development of user friendly, portable devices for at home use, such as those for COVID 19 or flu testing, is expanding this niche and will likely contribute more to the market's revenue in the coming years.

Point Of Care Molecular Diagnostics Market, By Geography

North America

Europe

Asia Pacific

Rest of the world

The Point of Care (POC) Molecular Diagnostics market is a globally expanding sector, with significant regional variations in adoption rates, growth drivers, and market maturity. While North America and Europe currently dominate the market due to their advanced healthcare infrastructure and robust regulatory frameworks, the Asia Pacific region is emerging as a high growth hub. Each region presents a unique set of opportunities and challenges shaped by economic development, disease burden, and healthcare policies.

United States Point Of Care Molecular Diagnostics Market

The United States holds the dominant position in the global POC molecular diagnostics market, accounting for a substantial share of the total revenue. This leadership is driven by several key factors, including a highly advanced healthcare infrastructure, significant investments in research and development, and the widespread adoption of molecular diagnostics in hospitals, clinics, and decentralized laboratories. A major trend in the U.S. is the growing demand for at home testing and the integration of POC devices with telehealth services, which enhances patient convenience and accessibility. The market is also fueled by the high prevalence of infectious diseases and chronic conditions, coupled with a strong emphasis on rapid and accurate diagnosis to improve patient outcomes.

Europe Point Of Care Molecular Diagnostics Market

Europe represents a mature and significant market for POC molecular diagnostics. The market's growth is propelled by the increasing prevalence of infectious diseases, a rising burden of chronic and genetic disorders, and a strong push for healthcare decentralization to improve efficiency and reduce costs. Countries like Germany and the UK are key contributors, benefiting from advanced healthcare systems and a focus on technological advancements. The regulatory landscape in Europe, while stringent, provides a stable environment for innovation. A key trend is the development of user friendly, portable devices that facilitate on site detection of a broad range of infectious diseases, with PCR based technologies dominating the market due to their high accuracy and rapid results.

Asia Pacific Point Of Care Molecular Diagnostics Market

The Asia Pacific region is poised to be the fastest growing market for POC molecular diagnostics. This rapid growth is driven by several factors, including improving healthcare infrastructure, a large and growing population, and increasing government initiatives to combat infectious diseases. Countries such as China, India, and Japan are at the forefront of this growth, with rising healthcare spending and a growing awareness of the benefits of early diagnosis. While cost remains a challenge, the region's increasing demand for accessible and affordable diagnostic solutions is pushing for localized manufacturing and the adoption of low cost, high volume testing platforms. The convergence of a high disease burden and a strong push for healthcare modernization makes this a prime region for future market expansion.

Latin America Point Of Care Molecular Diagnostics Market

The Latin America POC molecular diagnostics market is a developing sector with considerable growth potential. The market is driven by the high prevalence of infectious diseases, a growing awareness of healthcare, and government initiatives aimed at improving public health. Brazil and Mexico are key players in the region, benefiting from a large population base and increased healthcare expenditure. The adoption of POC diagnostics is particularly critical in rural and underserved areas, where access to centralized laboratories is limited. A key trend is the focus on rapid diagnostic tests for endemic infectious diseases like dengue, Zika, and HIV, which aids in disease surveillance and management.

Middle East & Africa Point Of Care Molecular Diagnostics Market

The Middle East and Africa (MEA) region presents a nascent but rapidly evolving market for POC molecular diagnostics. The market is driven by a high burden of infectious diseases, including HIV, tuberculosis, and malaria, and a growing recognition of the need for rapid diagnostic tools to manage outbreaks. Governments in the region, particularly in the GCC countries (e.g., Saudi Arabia and the UAE), are making significant investments in modernizing their healthcare infrastructure. The market is also benefiting from the increasing integration of AI and telemedicine, which helps to bridge the gap in healthcare access. However, challenges such as high costs and limited healthcare spending in certain parts of Africa can act as a restraint on growth, making strategic partnerships and government support crucial for market penetration.

Key Players

• The major players in the Point Of Care Molecular Diagnostics Market are:
• Abbott Laboratories Inc.
• Roche Diagnostics
• bioMerieux SA
• Danaher Corporation
• Cepheid, QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Hologic Inc.
• Bio Rad Laboratories Inc.
• Becton
• Dickinson and Company
• GenMark Diagnostics Inc.
• Meridian Bioscience Inc.
• Mesa Biotech Inc.
• Biocartis Group NV
• QuantuMDx Group Limited
• Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non economic factors
• Provision of market value (USD Billion) data for each segment and sub segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in depth analysis of the market of various perspectives through Porter's five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6 month post sales analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM UP APPROACH
• 2.9 TOP DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SERVICE TYPES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
• 3.2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT & SERVICE
• 3.8 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY TECHNOLOGY
• 3.9 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.10 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY END USER
• 3.11 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.12 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• 3.13 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• 3.14 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• 3.15 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY (USD BILLION)
• 3.16 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET EVOLUTION
• 4.2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTERS FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE PRODUCTS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY PRODUCT & SERVICE

• 5.1 OVERVIEW
• 5.2 ASSAYS & KITS
• 5.3 INSTRUMENTS & ANALYZERS
• 5.4 SOFTWARE & SERVICES

6 MARKET, BY TECHNOLOGY

• 6.1 OVERVIEW
• 6.2 RT PCR
• 6.3 INAAT

7 MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 CANCER
• 7.3 INFECTIOUS DISEASES
• 7.4 HEMATOLOGY
• 7.5 ENDOCRINOLOGY

8 MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS & CLINICS
• 8.3 DIAGNOSTIC CENTERS

9 MARKET, BY GEOGRAPHY

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 U.S.
  • 9.2.2 CANADA
  • 9.2.3 MEXICO
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 U.K.
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 JAPAN
  • 9.4.3 INDIA
  • 9.4.4 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 BRAZIL
  • 9.5.2 ARGENTINA
  • 9.5.3 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST AND AFRICA
  • 9.6.1 UAE
  • 9.6.2 SAUDI ARABIA
  • 9.6.3 SOUTH AFRICA
  • 9.6.4 REST OF MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY DEVELOPMENT STRATEGIES
• 10.3 COMPANY REGIONAL FOOTPRINT
• 10.4 ACE MATRIX
  • 10.4.1 ACTIVE
  • 10.4.2 CUTTING EDGE
  • 10.4.3 EMERGING
  • 10.4.4 INNOVATORS

11 COMPANY PROFILES

• 11.1 OVERVIEW
• 11.2 ABBOTT LABORATORIES INC.
• 11.3 ROCHE DIAGNOSTICS
• 11.4 BIOMERIEUX SA
• 11.5 DANAHER CORPORATION
• 11.6 CEPHEID
• 11.7 QIAGEN N.V.
• 11.8 THERMO FISHER SCIENTIFIC INC.
• 11.9 HOLOGIC INC.
• 11.10 BIO RAD LABORATORIES INC.
• 11.11 BECTON
• 11.12 DICKINSON AND COMPANY
• 11.13 GENMARK DIAGNOSTICS INC.
• 11.14 MERIDIAN BIOSCIENCE INC.
• 11.15 MESA BIOTECH INC.
• 11.16 BIOCARTIS GROUP NV
• 11.17 QUANTUMDX GROUP LIMITED

LIST OF TABLES AND FIGURES

• TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
• TABLE 2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 3 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 4 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 5 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 6 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY (USD BILLION)
• TABLE 7 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
• TABLE 8 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 9 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 10 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 11 NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 12 U.S. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 13 U.S. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 14 U.S. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 15 U.S. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 16 CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 17 CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 18 CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 19 CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 20 MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 21 MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 22 MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 23 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
• TABLE 24 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 25 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 26 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 27 EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 28 GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 29 GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 30 GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 31 GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 32 U.K. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 33 U.K. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 34 U.K. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 35 U.K. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 36 FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 37 FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 38 FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 39 FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 40 ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 41 ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 42 ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 43 ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 44 SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 45 SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 46 SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 47 SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 48 REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 49 REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 50 REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 51 REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 52 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
• TABLE 53 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 54 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 55 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 56 ASIA PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 57 CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 58 CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 59 CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 60 CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 61 JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 62 JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 63 JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 64 JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 65 INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 66 INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 67 INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 68 INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 69 REST OF APAC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 70 REST OF APAC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 71 REST OF APAC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 72 REST OF APAC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 73 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
• TABLE 74 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 75 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 76 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 77 LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 78 BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 79 BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 80 BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 81 BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 82 ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 83 ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 84 ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 85 ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 86 REST OF LATAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 87 REST OF LATAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 88 REST OF LATAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 89 REST OF LATAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 90 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (USD BILLION)
• TABLE 91 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 92 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 93 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 94 MIDDLE EAST AND AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 95 UAE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 96 UAE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 97 UAE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 98 UAE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 99 SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 100 SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 101 SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 102 SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 103 SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 104 SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 105 SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 106 SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 107 REST OF MEA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• TABLE 108 REST OF MEA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• TABLE 109 REST OF MEA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• TABLE 110 REST OF MEA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (USD BILLION)
• TABLE 111 COMPANY REGIONAL FOOTPRINT